Search research articles
Contact Us
Filters
Showing results (51-60 of 76) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Prostate Cancer and Prostatic Diseases
|
January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
A H Bryce, J J Alumkal, A Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2023
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
A Necchi, D Pouessel, R Leibowitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2023
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
A O Siefker-Radtke, N Matsubara, S H Park, et al.
Endocrine-Related Cancer
|
March 15, 2015
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
J Hadoux, D Malka, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2021
Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
M Aldea, L Cerbone, A Bayle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2023
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
J W F Catto, B Tran, M Rouprêt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
M Roupret, A Bertaut, G Pignot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 76) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Prostate Cancer and Prostatic Diseases
|
January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
A H Bryce, J J Alumkal, A Armstrong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2023
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201
A Necchi, D Pouessel, R Leibowitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2023
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
A O Siefker-Radtke, N Matsubara, S H Park, et al.
Endocrine-Related Cancer
|
March 15, 2015
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
J Hadoux, D Malka, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2021
Detection of additional occult malignancy through profiling of ctDNA in late-stage cancer patients
M Aldea, L Cerbone, A Bayle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2023
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
J W F Catto, B Tran, M Rouprêt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
M Roupret, A Bertaut, G Pignot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 20, 2024
TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes
Y Loriot, D P Petrylak, A Rezazadeh Kalebasty, et al.
Page
of 8